血浆胶质纤维酸性蛋白与tau蛋白:心脏骤停后神经功能结局的预测因子
本研究为瑞典三所医院2014-2018年的回顾性多中心观察性研究,纳入428例心脏骤停后入住ICU的患者(OHCA 328例,IHCA 100例),在ICU入科时、骤停后12小时和48小时采血检测GFAP、tau和NFL,以骤停后2-6个月Cerebral Performance Category 3-5定义不良神经结局。GFAP预测OHCA不良结局的AUC在入科时、12小时、48小时分别为0.76、0.86、0.91,tau相应为0.72、0.75、0.93;IHCA的预测性能略低。在部分患者中,12小时和48小时GFAP及48小时tau的预测价值与指南推荐的48小时NSE相近,而NFL在所有时间点均相似或优于GFAP和tau。作者认为GFAP和tau是有前景的神经预后标志物,48小时预测性能最高但不优于NFL。
要点
- OHCA后48小时GFAP预测不良神经结局AUC 0.91(95%CI 0.87-0.96),tau AUC 0.93(95%CI 0.89-0.96)。
- OHCA后12小时GFAP的AUC已达0.86(95%CI 0.81-0.90),作者认为其预测能力可能足以用于临床。
- IHCA后48小时GFAP的AUC为0.83(95%CI 0.71-0.95),tau为0.77(95%CI 0.65-0.90)。
- 在部分患者中,12小时和48小时GFAP及48小时tau的预测价值与48小时NSE相近。
- NFL在所有时间点的预测性能与GFAP和tau相似或更优。
适用人群与场景
- 2014-2018年瑞典三所医院ICU收治的心脏骤停后患者,共428例,其中院外心脏骤停(OHCA)328例、院内心脏骤停(IHCA)100例。
- 不良神经结局定义为心脏骤停后2-6个月Cerebral Performance Category 3-5。
诊断标准与关键阈值
- 不良神经结局:心脏骤停后2-6个月Cerebral Performance Category 3-5。
- 预测性能以受试者工作特征曲线下面积(AUC)评价。
研究设计与关键结果
- 研究类型:回顾性多中心观察性研究,三所医院,纳入428例心脏骤停后入住ICU患者(OHCA 328例,IHCA 100例)。
- 采血时间点:ICU入科时、心脏骤停后12小时和48小时;血浆回顾性检测GFAP、tau和NFL,血清NSE按临床常规检测。
- OHCA:GFAP预测不良神经结局的AUC(95%CI)在入科时0.76(0.70-0.82)、12小时0.86(0.81-0.90)、48小时0.91(0.87-0.96);tau相应为0.72(0.66-0.79)、0.75(0.69-0.81)、0.93(0.89-0.96)。
- IHCA:GFAP的AUC(95%CI)在入科时0.77(0.66-0.87)、12小时0.83(0.74-0.92)、48小时0.83(0.71-0.95);tau相应为0.61(0.49-0.74)、0.68(0.56-0.79)、0.77(0.65-0.90)。
- 在时间点之间加入标志物水平变化,与仅用最后时间点相比未提高预测准确性。
- 在部分患者中,OHCA和IHCA后12小时和48小时GFAP以及48小时tau,与48小时NSE(指南推荐的最早时间点)预测价值相近。
- NFL在OHCA和IHCA后所有时间点的预测性能与GFAP和tau相似或更优。
证据类型、等级与局限
- 证据类型:回顾性多中心观察性研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为GFAP和tau是有前景的神经预后标志物,在OHCA后48小时预测性能最高,但不优于NFL。
- 作者认为GFAP在心脏骤停后12小时的预测能力可能足以用于临床。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The purpose was to evaluate glial fibrillary acidic protein (GFAP) and total-tau in plasma as predictors of poor neurological outcome after out-of-hospital (OHCA) and in-hospital cardiac arrest (IHCA), including comparisons with neurofilament light (NFL) and neuron-specific enolase (NSE).
METHODS: Retrospective multicentre observational study of patients admitted to an intensive care unit (ICU) in three hospitals in Sweden 2014-2018. Blood samples were collected at ICU admission, 12 h, and 48 h post-cardiac arrest. Poor neurological outcome was defined as Cerebral Performance Category 3-5 at 2-6 months after cardiac arrest. Plasma samples were retrospectively analysed for GFAP, tau, and NFL. Serum NSE was analysed in clinical care. Prognostic performances were tested with the area under the receiver operating characteristics curve (AUC).
RESULTS: Of the 428 included patients, 328 were OHCA, and 100 were IHCA. At ICU admission, 12 h and 48 h post-cardiac arrest, GFAP predicted neurological outcome after OHCA with AUC (95% CI) 0.76 (0.70-0.82), 0.86 (0.81-0.90) and 0.91 (0.87-0.96), and after IHCA with AUC (95% CI) 0.77 (0.66-0.87), 0.83 (0.74-0.92) and 0.83 (0.71-0.95). At the same time points, tau predicted outcome after OHCA with AUC (95% CI) 0.72 (0.66-0.79), 0.75 (0.69-0.81), and 0.93 (0.89-0.96) and after IHCA with AUC (95% CI) 0.61 (0.49-0.74), 0.68 (0.56-0.79), and 0.77 (0.65-0.90). Adding the change in biomarker levels between time points did not improve predictive accuracy compared to the last time point. In a subset of patients, GFAP at 12 h and 48 h, as well as tau at 48 h, offered similar predictive value as NSE at 48 h (the earliest time point NSE is recommended in guidelines) after both OHCA and IHCA. The predictive performance of NFL was similar or superior to GFAP and tau at all time points after OHCA and IHCA.
CONCLUSION: GFAP and tau are promising biomarkers for neuroprognostication, with the highest predictive performance at 48 h after OHCA, but not superior to NFL. The predictive ability of GFAP may be sufficiently high for clinical use at 12 h after cardiac arrest.
参考来源
- Arctaedius I, Levin H, Thorgeirsdóttir B, et al. Plasma glial fibrillary acidic protein and tau: predictors of neurological outcome after cardiac arrest. Crit Care. 2024. PMID: 38594704. doi:10.1186/s13054-024-04889-0
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。